XIENCE 28 USA Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1605 participants.

Also called NCT03815175

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,605 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03815175
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Canada, China, Germany, Hong Kong SAR China, Italy, Netherlands, Portugal, Singapore, Spain, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03815175. Allocation not applicable; no masking; primary purpose treatment. Start 2019-02-25 (actual); primary completion 2020-08-14 (actual). Results posted on 2021-12-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
XIENCE 28 USA Study
Condition
Bleeding Disorder
Condition
Hemorrhagic Stroke
Condition
Hematological Diseases
Condition
Thrombocytopenia
Condition
Coagulation Disorder
Condition
Anemia
Condition
Renal Insufficiency
Intervention (Device)
XIENCE
Intervention (Drug)
DAPT (aspirin and/or P2Y12 receptor inhibitor)
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03815175
Content hash
a2b2d285621b6b023a41652578d2aadc699a7e295841c93afe515b07402fe9af